Analytical and Clinical Validation of Biomarkers for Alzheimers Disease (AD) and AD-Related Dementias (ADRD) (U01 Clinical Trial Optional) | PAR 25 209

Frequently Asked Questions (FAQs)

What is this NIH funding opportunity?

This is a National Institutes of Health (NIH) cooperative agreement opportunity using the U01 mechanism (Clinical Trial Optional) titled "Analytical and Clinical Validation of Biomarkers for Alzheimers Disease (AD) and AD-Related Dementias (ADRD)." The opportunity number is PAR 25 209.

What is the main goal of PAR 25 209?

The central aim is to speed up the development of AD/ADRD biomarkers that are dependable enough for real-world use. That includes use in therapeutic and medical product discovery and development, clinical trial design and execution, and potentially routine clinical practice.

Is this opportunity focused on discovering new biomarkers?

No. The emphasis is not on early discovery of new candidate markers. It is focused on the careful, systematic work needed to show that an existing biomarker (or a composite/signed set of biomarkers) performs reliably and meaningfully for a specific, defined purpose.

What types of projects does this NOFO support?

This NOFO specifically supports projects focused on analytical validation and/or clinical validation of biomarkers for AD and AD-related dementias.

What does "analytical validation" mean in this NOFO?

Analytical validation is about demonstrating that the biomarker measurement itself is accurate, precise, reproducible, and robust under real-world conditions that matter. Examples of conditions called out include variation across operators, sites, instruments, lots, runs, and sample handling conditions.

What does "clinical validation" mean in this NOFO?

Clinical validation is about demonstrating that the biomarker readout is clinically meaningful for a stated context of use. Example contexts of use described include identifying or enriching for a particular AD/ADRD population, tracking disease progression, predicting risk, or supporting clinical trial endpoints.

Can a project focus on only analytical validation or only clinical validation?

Yes. The NOFO supports analytical validation and/or clinical validation, indicating that a project may propose one or both, as long as the work is aligned with the opportunity goals and rigor expectations.

What level of rigor is expected for validation studies?

The NOFO indicates that the validation rigor is expected to be comparable to what the FDA expects under its Biomarker Qualification Program (BQP) or other relevant FDA regulatory pathways. This implies a high bar for study design, documentation, statistical rigor, standardization, and evidence quality.

Why does the NOFO reference the FDA Biomarker Qualification Program (BQP)?

The reference signals that NIH is looking for evidence that can stand up to regulatory scrutiny and be broadly trusted by researchers, product developers, and clinicians, with methods and documentation aligned to expectations used in FDA-related qualification or similar regulatory processes.

What is meant by a "defined purpose" or "context of use" for a biomarker?

It means the biomarker should be validated for a clearly stated application, such as population identification/enrichment, progression tracking, risk prediction, or supporting clinical trial endpoints, rather than being presented as generally useful without a specific use case.

Are composite biomarkers or biomarker signatures allowed?

Yes. The opportunity description explicitly includes a biomarker or a composite/signed set of biomarkers, as long as the validation work demonstrates reliable performance for the defined purpose.

What is the funding mechanism and what does it imply?

The funding mechanism is a cooperative agreement (U01). This typically means NIH staff will have substantial programmatic involvement compared with a standard grant, and applicants should anticipate an active partnership structure.

How involved will NIH be during the project?

The description indicates NIH may help guide key aspects such as milestones, coordination, and alignment with broader program goals, reflecting substantial programmatic involvement typical of cooperative agreements.

Is a clinical trial required?

No. The mechanism is described as "Clinical Trial Optional," meaning a clinical trial is not required by default. Applicants would propose what is appropriate for their validation plan within the scope described.

What is the CFDA number and funding category for this opportunity?

The opportunity is associated with CFDA number 93.866 and is categorized as discretionary funding in the health area.

What is the application due date?

The original application due date provided is March 5, 2026.

When was the opportunity created?

The opportunity was created on November 14, 2024.

Does the excerpt provide an award ceiling or expected number of awards?

No. The excerpted information states that an award ceiling and expected number of awards are not provided in the source data shown. Applicants would need to consult the full announcement for budget limits, project period expectations, and review considerations.

Who is eligible to apply?

Eligibility is broad and includes many types of domestic applicants, such as state, county, and local governments; special districts; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities/Indian housing authorities; nonprofits (501(c)(3) and non-501(c)(3), excluding institutions of higher education in those nonprofit categories); for-profit organizations other than small businesses; and small businesses.

Are minority-serving institutions explicitly included as eligible?

Yes. The NOFO highlights eligibility for Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving institutions, HBCUs, and TCCUs.

Are faith-based or community-based organizations eligible?

Yes. The NOFO explicitly lists faith-based or community-based organizations among the eligible applicant categories.

Are U.S. territories or possessions eligible to apply?

Yes. U.S. territories or possessions are explicitly included in the listed eligible applicant categories.

Are non-U.S. entities (foreign organizations) eligible to apply?

Yes. The NOFO explicitly includes non-U.S. entities (foreign organizations) among the eligible applicant categories.

What kinds of teams are a good fit for this opportunity?

The opportunity is designed for teams that already have a promising AD/ADRD biomarker approach and are ready to perform rigorous analytical and/or clinical validation to make the biomarker reliable, standardized, and fit for a clearly defined purpose.

What outcomes is NIH trying to enable with validated biomarkers?

The description emphasizes enabling confident real-world use, including supporting therapeutic and medical product discovery and development, improving clinical trial design and execution, and potentially supporting routine clinical practice.

What kinds of evidence or study qualities are emphasized?

The opportunity emphasizes rigorous evidence generation, including standardization and documentation, and statistical rigor that aligns with FDA-level expectations for biomarker qualification or related regulatory pathways.